Managing Adverse Events with New Therapeutic Approaches

Earn CME:

In this webcast from the 'Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing' symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses the best practices for the management of adverse events associated with therapies utilized in the treatment of hepatocellular carcinoma (HCC).

© 2019 Imedex, an HMP Company

Imedex,CME,Continuing Medical Education,Education,Accreditation,Medical,Nurse,Residents-in-Training,Fellows,Physician,Clinician,Physician-in-training,HMP CME,gi cancer,gi malignancy,gi malignancies,gastrointestinal cancer,gastrointestinal malignancies,hcc,hepatocellular carcinoma,liver cancer,adverse events,AE profile,AE,immunotherapy,immune-related adverse events,irAE,irAEs,